Early Access

10-KPeriod: FY2018

THERMO FISHER SCIENTIFIC INC. Annual Report, Year Ended Dec 31, 2018

Filed February 27, 2019For Securities:TMO

Summary

Thermo Fisher Scientific Inc. (TMO) reported strong performance for the fiscal year ending December 30, 2018. The company demonstrated significant revenue growth, driven by both organic demand across its key end markets and strategic acquisitions, notably the acquisition of Patheon N.V. in the previous year, which bolstered its Laboratory Products and Services segment. This growth was particularly robust in Asia. The company also highlighted its ongoing commitment to innovation and operational efficiency through productivity improvements. Financially, Thermo Fisher reported an increase in operating income and operating income margin, reflecting its ability to translate sales growth into profitability. The company maintained a healthy cash flow from operations and managed its debt effectively, with ample borrowing capacity for future needs. Management expressed confidence in its ability to fund ongoing operations and strategic initiatives, including the pending acquisition of Gatan Inc., indicating a positive outlook for continued growth and value creation for shareholders.

Financial Statements
Beta
Revenue$24.36B
R&D Expenses$967.00M
SG&A Expenses$6.06B
Operating Expenses$20.57B
Operating Income$3.78B
Interest Expense$667.00M
Net Income$2.94B
EPS (Basic)$7.31
EPS (Diluted)$7.24
Shares Outstanding (Basic)402.00M
Shares Outstanding (Diluted)406.00M

Key Highlights

  • 1Revenue increased by $3.44 billion to $24.36 billion in 2018, driven by $1.53 billion from acquisitions and 8% organic growth.
  • 2Operating income grew to $3.78 billion in 2018, with an operating income margin of 15.5%, up from $2.96 billion and 14.2% in 2017.
  • 3The Life Sciences Solutions segment saw strong demand, with sales increasing by 9% to $6.27 billion, and operating income margin improved to 34.4%.
  • 4The Analytical Instruments segment grew sales by 13% to $5.47 billion, with operating income margin increasing to 22.8%.
  • 5The Laboratory Products and Services segment experienced significant growth, with sales up 28% to $10.04 billion, largely due to the Patheon acquisition.
  • 6The company maintained a strong liquidity position, with $2.10 billion in cash and cash equivalents as of December 31, 2018, and sufficient borrowing capacity.
  • 7Thermo Fisher is actively pursuing strategic acquisitions, with the pending acquisition of Gatan Inc. for approximately $925 million.

Frequently Asked Questions